Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
BJU International|October 31, 2023
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancerMarkus von Deimling, Marc Furrer, Laura S Mertens, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCGCarlo Buonerba, Raffaele Baio, Felice Crocetto, et al.
Urologic Oncology|June 8, 2022
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancerMatteo Ferro, Biagio Barone, Felice Crocetto, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin ImmunotherapyMatteo Ferro, Octavian Sabin Tătaru, Gennaro Musi, et al.
Minerva Urology and Nephrology|October 5, 2022
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCGRoberto Contieri, Rodolfo Hurle, Marco Paciotti, et al.
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
Cancers|April 13, 2023
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-AnalysisFrancesco Del Giudice, Vincenzo Asero, Eugenio Bologna, et al.
Clinical Genitourinary Cancer|September 4, 2023
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaMatteo Ferro, Sever Chiujdea, Mihai Dorin Vartolomei, et al.
Future Oncology (London, England)|July 19, 2021
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapyMatteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Pageof 25